CORDIS
EU research results

CORDIS

English EN
New Approaches to Target Tuberculosis

New Approaches to Target Tuberculosis

Objective

The increasing emergence of multidrug resistant strains and extensively drug resistant strains, the last one being virtually untreatable, urgently demand novel drugs for therapy of tuberculosis. This project has the aim of bringing together a number of research scientists with expertise in a broad range of disciplines, both from Europe and from India, covering the development field from chemistry to in vivo evaluation. The selected targets belong to either the group of targets from which some proof of concept already exist (mycolic acid synthesis and ATP synthase) either to the group of completely new targets that will be validated (thymidylate synthase, acyl-CoA carboxylase, DNA helicases). One alternative strategy to target the host cellular machinery to enhance bacterial killing is, likewise, included. The selected targets are covering fatty acid metabolism, nucleoside synthesis, energy generator, the survival of the microorganism in macrophages, the nucleic acids metabolism. The systems selected include those from which we expect to generate compounds active against replicating mycobacteria or to obtain compounds targeting latent infection. The application is divided in four scientific workpackages, including target validation, the interaction with the host cellular machinery, the design and synthesis of new inhibition and in vitro and in vivo screening of drug candidates and one management workpackage. A considerable part of the drug development and assessment against drug resistant Mycobacterium tuberculosis will be carried out by the Indian partners, one of which is an SME.

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

Address

Oude Markt 13
3000 Leuven

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 608 000

Administrative Contact

Maria Vereeken (Ms.)

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 1 052 135

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 404 640

MEDICAL RESEARCH COUNCIL

United Kingdom

EU Contribution

€ 453 463

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 245 720

NATIONAL INSTITUTE OF IMMUNOLOGY SOCIETY

India

EU Contribution

€ 55 800

National Institute of Pharmaceutical Education and Research

India

EU Contribution

€ 86 400

Institute of Molecular Medicine

India

EU Contribution

€ 88 320

Project information

Grant agreement ID: 222965

Status

Closed project

  • Start date

    1 October 2008

  • End date

    30 September 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 938 167,50

  • EU contribution

    € 2 994 478

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

This project is featured in...